scholarly journals An Update on Psychotic Depression

10.5772/31564 ◽  
2012 ◽  
Author(s):  
John Matthews
Keyword(s):  
Psychotic Depression

Clinical and psychometric validation of the psychotic depression assessment scale

2015 ◽  
Vol 173 ◽  
pp. 261-268 ◽  
Author(s):  
Søren D. Østergaard ◽  
Christina H. Pedersen ◽  
Peter Uggerby ◽  
Povl Munk-Jørgensen ◽  
Anthony J. Rothschild ◽  
...  
Keyword(s):  
Assessment Scale ◽  
Psychometric Validation ◽  
Psychotic Depression ◽  
Depression Assessment

Association between psychomotor disturbance and treatment outcome in psychotic depression: a STOP-PD II report

2021 ◽  
pp. 1-7
Author(s):  
Alastair J. Flint ◽  
Kathleen S. Bingham ◽  
Nicholas H. Neufeld ◽  
George S. Alexopoulos ◽  
Benoit H. Mulsant ◽  
...  
Keyword(s):  
Treatment Outcome ◽  
Acute Phase ◽  
Controlled Trial ◽  
Future Research ◽  
Psychotic Depression ◽  
Regression Analyses ◽  
Open Label ◽  
Randomized Controlled ◽  
Stabilization Phase ◽  
The Relationship

Abstract Background Little is known about the relationship between psychomotor disturbance (PMD) and treatment outcome of psychotic depression. This study examined the association between PMD and subsequent remission and relapse of treated psychotic depression. Methods Two hundred and sixty-nine men and women aged 18–85 years with an episode of psychotic depression were treated with open-label sertraline plus olanzapine for up to 12 weeks. Participants who remained in remission or near-remission following an 8-week stabilization phase were eligible to participate in a 36-week randomized controlled trial (RCT) that compared the efficacy and tolerability of sertraline plus olanzapine (n = 64) with sertraline plus placebo (n = 62). PMD was measured with the psychiatrist-rated sign-based CORE at acute phase baseline and at RCT baseline. Spearman's correlations and logistic regression analyses were used to analyze the association between CORE total score at acute phase baseline and remission/near-remission and CORE total score at RCT baseline and relapse. Results Higher CORE total score at acute phase baseline was associated with lower frequency of remission/near-remission. Higher CORE total score at RCT baseline was associated with higher frequency of relapse, in the RCT sample as a whole, as well as in each of the two randomized groups. Conclusions PMD is associated with poorer outcome of psychotic depression treated with sertraline plus olanzapine. Future research needs to examine the neurobiology of PMD in psychotic depression in relation to treatment outcome.

P.2.b.003 Mirtazapine versus sertraline in the treatment of post-psychotic depression

2013 ◽  
Vol 23 ◽  
pp. S320
Author(s):  
D. Vasile ◽  
O. Vasiliu ◽  
A.G. Mangalagiu ◽  
G.A. Sopterean ◽  
R.E. Bratu
Keyword(s):  
Psychotic Depression

Abnormalities of the HPA axis in affective disorders: clinical subtypes and potential treatments

2006 ◽  
Vol 18 (5) ◽  
pp. 193-209 ◽  
Author(s):  
Richard J. Porter ◽  
Peter Gallagher
Keyword(s):  
Bipolar Disorder ◽  
Cognitive Impairment ◽  
Hpa Axis ◽  
Affective Disorders ◽  
Psychotic Depression ◽  
Review Of The Literature ◽  
Hpa Axis Dysregulation ◽  
New Evidence ◽  
The Brain

Background:New evidence is emerging regarding abnormalities of hypothalamic-pituitary-adrenal (HPA) axis function in subtypes of affective disorders. Adverse effects of HPA axis dysregulation may include dysfunction of monoaminergic transmitter systems, cognitive impairment and peripheral effects. Newer treatments specifically targeting the HPA axis are being developed.Objective:To review these developments focusing particularly on the glucocorticoid receptor (GR) antagonist mifepristone.Method:A selective review of the literature.Results:The function of GRs is increasingly being defined. The role of corticotrophin-releasing hormone (CRH) and dehydroepiandrosterone (DHEA) in the brain is also increasingly understood. HPA axis function is particularly likely to be abnormal in psychotic depression and bipolar disorder, and it is in these conditions that trials of the GR antagonist mifepristone are being focused. CRH antagonists and DHEA are also being investigated as potential treatments.Conclusion:Initial studies of mifepristone and other HPA-axis-targeting agents in psychotic depression and bipolar disorder are encouraging and confirmatory studies are awaited.

Prolactin secretion in response to haloperidol challenge in delusional (psychotic) and non-delusional depression

2000 ◽  
Vol 15 (8) ◽  
pp. 480-482 ◽  
Author(s):  
L Lykouras ◽  
M Markianos ◽  
J Hatzimanolis ◽  
P Oulis ◽  
G.N Christodoulou
Keyword(s):  
Major Depressive Episode ◽  
Prolactin Secretion ◽  
Psychotic Depression ◽  
Major Depressive ◽  
Time Effects ◽  
Delusional Depression ◽  
Neurotransmitter Activity ◽  
Patient Groups ◽  
Dsm Iv ◽  
Psychotic Features

Certain studies on measures related to central neurotransmitter activity have demonstrated that in delusional (psychotic) depression there is a dopaminergic dysregulation which distinguishes it from non-psychotic depression. A neuroendocrinologic method to check the degree of DA receptor responsivity is by measuring the prolactin responses to acute intramuscular administration of haloperidol. We studied this possibility by applying the haloperidol test in seven delusional and ten non-delusional depressed patients. All patients met DSM-IV criteria for a major depressive episode, single or recurrent, with or without psychotic features. After a three-week washout period, 5 mg of haloperidol were injected i.m. and blood samples were taken at 0, 30, 60, 90 and 120 minutes. In both trials, significant time effects were observed (elevated prolactin levels, F = 11.36, P = 0.000). However, the prolactin responses to haloperidol did not differ significantly between the two patient groups (F = 0.12, P = 0.97). These data do not show a difference in D2 receptor responsivity, at least at the hypothalamus-pituitary level, between psychotic and non-psychotic depression.

Selection of treatment for psychotic depression: questionnaires for psychiatrists

1999 ◽  
Vol 14 (1) ◽  
pp. 53-54
Author(s):  
T Takahashi ◽  
S Oyamada ◽  
Y Yoshimura ◽  
A Oshima ◽  
A lwanamia ◽  
...  
Keyword(s):  
Psychotic Depression ◽  
Selection Of

Content and Consistency in the Endogenous Depressive Pattern

1966 ◽  
Vol 112 (486) ◽  
pp. 471-484 ◽  
Author(s):  
Saul H. Rosenthal ◽  
Gerald L. Klerman
Keyword(s):  
19Th Century ◽  
The Other ◽  
Psychotic Depression ◽  
Public Attention ◽  
Half Century ◽  
Manic Depressive ◽  
Wide Range ◽  
The 19Th Century ◽  
Mourning And Melancholia ◽  
The Way

As currently used, the diagnosis of depression includes a wide range of clinical phenomena. This has not always been the case. Near the end of the 19th century, when the term depression began to evolve the meanings that it has today it was applied primarily to psychotics. The formulations of Freud in Mourning and Melancholia (1917), and of Kraepelin in Manic Depressive Insanity (1921) were based upon observations of patients who were both depressed and psychotic. In their work the contrast was between psychotic depression (or “melancholia”) on one hand, and normal sadness on the other. In the succeeding half-century, however, as psychiatry has extended its boundaries, increasing attention has been focused on non-psychotic depressions, often called “neurotic” or “reactive.” As these “neurotic” or “reactive” depressions reached public attention, a debate began over the way in which the depressive population should be described and the extent to which it should be subdivided. Critical and often sarcastic written battles were fought between the separatists and the unifiers during the 1920's and 1930's. These debates have been informatively chronicled by Partridge (1949). We have found it useful to divide these theorists into unifiers, dualists, and pluralists.

Sign in / Sign up

Export Citation Format

Share Document